Document is current
Any future updates will be listed below
-
Authors
Brown, Nicole L.
Howell, Sacha J.
Papantoniou, Dimitrios
Eriksson, Olle
Bergqvist, Mattias
Williams, Amy
Kavanagh, Amy
Backlund, Alexandra
Albu-Kareem, Ahmed
Elinder, Ellinor
Larsson, Karolina
Uminska, Monika
Ekholm, Maria https://orcid.org/0000-0002-5553-5323
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04597580 at ClinicalTrials.govDocuments that mention this clinical trial
Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors
https://doi.org/10.1007/s10549-025-07879-0
-
Funding
Funding for this research was provided by:
The Christie Charity (charity number 1201654)
Cancerfonden (23 2760 Fk)
ALF grants from Region Östergötland (RÖ-1013092)
Forskningsrådet i Sydöstra Sverige (FORSS-989664, FORSS-995301)
Swedish Breast Cancer Association (F2018-03, F2019-005)
Percy Falk Foundation (2018, 2019)
Foundation for Clinical Cancer Research in Jönköping (180424-2, 20201116-1)
Futurum - Akademin för Hälsa och Vård, Region Jönköpings läns (FUTURUM- 989624)
Svenska Läkaresällskapet (SLS-874931)
Linköping University
- License Information
-
More Information
Article History
Received: 13 October 2025
Accepted: 10 December 2025
First Online: 11 February 2026
Declarations
:
: Sacha Howell declares advisory board roles with Eli Lilly, speaker fees from AstraZeneca, Pfizer, Eli Lilly and Novartis, travel and accommodation support from AstraZeneca and Novartis, grant funding for a joint working agreement with Eli Lilly, and a research collaboration with Biovica International (see Funding section). Dimitrios Papantoniou declares advisory board and expert testimony roles with MSD, AstraZeneca, Janssen, and Merck, and speaker fees from Ipsen. Mattias Bergqvist is an employee of Biovica International AB and is listed as an inventor on two registered patents (WO2023209181, WO2023208361) and one pending patent related to the DiviTum assay. Amy Williams is an employee of Biovica International AB and is listed as an inventor on two registered patents (WO2023209181, WO2023208361) and one pending patent related to the DiviTum assay. Karolina Larsson declares an advisory board role with Pfizer. Maria Ekholm declares advisory board roles with AstraZeneca, Daiichi Sankyo, Eli Lilly, Novartis, and Pfizer; institutional funding from MSD; and a research collaboration with Biovica International (see Funding section). All remaining authors declare no competing interests.
: The study was approved by the ethics committees in the United Kingdom (19/WS/0012, 15 Feb 2019) and Sweden (2019-05238, 6 Nov 2019). All procedures were conducted in accordance with the Declaration of Helsinki.
: Not applicable (no identifiable individual patient data are included).
: Written informed consent was obtained from all individual participants included in the study.
